CommercialBilling CodesMedium impact
07.03.26b, Tumor Treating Fields
Independence Blue Cross·Oncology, Neurology, Neurosurgery·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued Policy 07.03.26b on Tumor Treating Fields (TTFields) effective 01/01/2026, adding CPT code 1025T for dosimetry and simulation modeling as medically necessary. This is a minor update to communicate the company's continuing position; coverage criteria for newly diagnosed and recurrent glioblastoma remain unchanged, but billing teams must now recognize 1025T as a separately billable service.
Action Required
By 01/01/2026: Billing team must update system to recognize CPT code 1025T as a medically necessary service for Tumor Treating Fields therapy. Ensure that 1025T claims for TTFields dosimetry and simulation modeling are submitted separately from the device code E0766. Verify that E0766 continues to be reimbursed as a single monthly payment for device and supplies, and confirm that replacement supplies (A4555) are NOT billed separately. Update any internal billing guidelines, encounter templates, or prior authorization workflows to include code 1025T. Claims submitted without recognition of 1025T may be underbilled or denied. Providers should document that all coverage criteria are met (histologically confirmed glioblastoma, supratentorial location, KPS >60, completed standard therapy, willingness to use device 18+ hours daily, and adjuvant temozolomide for newly diagnosed cases). Billing team should also review the policy's exclusion criteria (implanted devices, arrhythmias, increased ICP) and ensure providers document absence of these contraindications.